CL2021002621A1 - Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria - Google Patents

Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria

Info

Publication number
CL2021002621A1
CL2021002621A1 CL2021002621A CL2021002621A CL2021002621A1 CL 2021002621 A1 CL2021002621 A1 CL 2021002621A1 CL 2021002621 A CL2021002621 A CL 2021002621A CL 2021002621 A CL2021002621 A CL 2021002621A CL 2021002621 A1 CL2021002621 A1 CL 2021002621A1
Authority
CL
Chile
Prior art keywords
pyrazino
hexahydro
treatment
autoimmune disease
pyrazine compounds
Prior art date
Application number
CL2021002621A
Other languages
English (en)
Spanish (es)
Inventor
Yongfu Liu
Buyu Kou
Hong Shen
Zhisen Zhang
Lue Dai
Fabian Dey
Wei Zhu
Zhiwei Zhang
Yafei Liu
Haixia Liu
Linuo Zhu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2021002621A1 publication Critical patent/CL2021002621A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CL2021002621A 2019-04-09 2021-10-06 Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria CL2021002621A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019081900 2019-04-09
CN2019121598 2019-11-28
CN2020078225 2020-03-06

Publications (1)

Publication Number Publication Date
CL2021002621A1 true CL2021002621A1 (es) 2022-05-13

Family

ID=70228042

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002621A CL2021002621A1 (es) 2019-04-09 2021-10-06 Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria

Country Status (19)

Country Link
US (1) US20220340597A1 (https=)
EP (1) EP3953356B1 (https=)
JP (1) JP7692838B2 (https=)
KR (1) KR20210149163A (https=)
CN (1) CN113710672B (https=)
AU (1) AU2020272467A1 (https=)
BR (1) BR112021020297A2 (https=)
CA (1) CA3135129A1 (https=)
CL (1) CL2021002621A1 (https=)
CO (1) CO2021013166A2 (https=)
CR (1) CR20210513A (https=)
IL (1) IL286870A (https=)
MA (1) MA55594A (https=)
MX (1) MX2021012223A (https=)
PE (1) PE20212178A1 (https=)
PH (1) PH12021552533A1 (https=)
SG (1) SG11202110401WA (https=)
TW (1) TW202104230A (https=)
WO (1) WO2020207991A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11998539B2 (en) 2019-11-28 2024-06-04 Bayer Aktiengesellschaft Substituted aminoquinolones as DGKalpha inhibitors for immune activation

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021084022A1 (en) * 2019-10-31 2021-05-06 F. Hoffmann-La Roche Ag Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
CN114728959B (zh) * 2019-11-12 2024-11-12 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢吡嗪并[1,2-b]异喹啉化合物
US12503471B2 (en) 2019-11-19 2025-12-23 Hoffmann-La Roche Inc. Triazatricycle compounds for the treatment of autoimmune disease
CN114728976B (zh) 2019-11-19 2024-08-16 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物
WO2021110614A1 (en) * 2019-12-03 2021-06-10 F. Hoffmann-La Roche Ag HYDROPYRIDO[1,2-α]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
US20240317735A1 (en) * 2020-07-14 2024-09-26 Hoffmann-La Roche Inc. Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103562201B (zh) * 2011-01-12 2016-10-19 帆德制药股份有限公司 作为toll样受体调节剂的取代的苯并氮杂卓
RS56747B1 (sr) 2012-09-14 2018-03-30 Hoffmann La Roche Pirazol derivati karboksamida kao taar modulatori za upotrebu u lečenju nekoliko poremećaja, kao što su depresija, dijabetes i parkinsonova bolest
CN105992766A (zh) * 2013-12-13 2016-10-05 武田药品工业株式会社 作为tlr抑制剂的吡咯并[3,2-c]吡啶衍生物
CA3005766A1 (en) 2015-12-17 2017-06-22 Merck Patent Gmbh Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
EP3807271A1 (en) * 2018-06-13 2021-04-21 F. Hoffmann-La Roche AG Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease
JP2022501401A (ja) * 2018-09-27 2022-01-06 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 自己免疫疾患の治療のためのヘテロシクリル化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11998539B2 (en) 2019-11-28 2024-06-04 Bayer Aktiengesellschaft Substituted aminoquinolones as DGKalpha inhibitors for immune activation

Also Published As

Publication number Publication date
PH12021552533A1 (en) 2022-06-20
CN113710672A (zh) 2021-11-26
AU2020272467A1 (en) 2021-10-14
EP3953356A1 (en) 2022-02-16
CO2021013166A2 (es) 2021-12-10
SG11202110401WA (en) 2021-10-28
CR20210513A (es) 2021-11-02
IL286870A (en) 2021-10-31
TW202104230A (zh) 2021-02-01
WO2020207991A1 (en) 2020-10-15
KR20210149163A (ko) 2021-12-08
BR112021020297A2 (pt) 2021-12-14
CA3135129A1 (en) 2020-10-15
PE20212178A1 (es) 2021-11-09
CN113710672B (zh) 2025-01-03
EP3953356B1 (en) 2023-07-26
US20220340597A1 (en) 2022-10-27
MA55594A (fr) 2022-02-16
JP2022527588A (ja) 2022-06-02
JP7692838B2 (ja) 2025-06-16
MX2021012223A (es) 2021-11-03
EP3953356C0 (en) 2023-07-26

Similar Documents

Publication Publication Date Title
CL2021002621A1 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
CO2025010435A2 (es) Compuestos tricíclicos para el tratamiento de cáncer
CO2022008091A2 (es) Inhibidores de kras g12c
ECSP22050936A (es) Compuestos tric?clicos sustituidos
CO2021015698A2 (es) Moduladores de thr-β y métodos de uso de estos
CL2022000271A1 (es) Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina.
AR126854A1 (es) Compuestos macrocíclicos para el tratamiento de cáncer
CO2022001094A2 (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas
MX2020008754A (es) Compuestos farmaceuticos.
MX2018011831A (es) Antagonistas solubles de receptor de c5aa(c5ar).
MX2021005754A (es) Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cancer.
CO2020014677A2 (es) Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
AR133266A1 (es) Macrociclos para el tratamiento de enfermedades autoinmunitarias
AR133199A1 (es) Macrociclos bicíclicos para el tratamiento de enfermedades autoinmunitarias
CL2019001023A1 (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia.
UY39181A (es) COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO
MX2020007443A (es) Derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona y compuestos relacionados como moduladores del receptor c5a para el tratamiento de vasculitis y enfermedades inflamatorias.
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
CO2024003401A2 (es) Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades autoinmunitarias
CL2024001524A1 (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
MX2020008706A (es) Nuevos compuestos de opioides y sus usos.
AR131945A1 (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno